News

GREENEARTH ENERGY PARTNERS UP WITH ISRAEL’S ZENITH SOLAR AND RECEIVES PLANNING APPROVAL

Share |
Monday, September 5th, 2011

Greenearth Energy Limited (ASX:GER) is pleased to announce that the company’s subsidiary Greenearth Solar Energy has received planning approval from City of Port Philip for its ZenithSolar Z20 High Concentration Photovoltaic (HCPV)/Combined Heat and Power (CHP) solar technology demonstration at 69 Fennell Street Port Melbourne.

The demonstration site with its unique central location will allow potential investors, project developers and offtake customers alike, easy access to the state-of-the art technology. Eight Z20 units on the site will produce a peak output of 88kW thermal energy (hot water) and 36kW of electrical energy.

The successful operation of the ZenithSolar Z20 CHP solar technology at Kibbutz Yavne in Israel has demonstrated the benefits of the technology which include:
• Combined Heat and Power generation (CHP)
• Industry leading combined efficiency of greater than 75%
• Dual output (Heat and Power) improves project ROI
• System design allows for easy upgrades
• Modular Installations with small footprint
• Proven field performance

In late 2010, Greenearth Solar Energy and ZenithSolar signed a Conditional Distribution Agreement under which a trial of the ZenithSolar Z20 technology will be carried out in Victoria. A successful trial will result in Greenearth Solar Energy and ZenithSolar establishing an Exclusive Distribution Agreement for the technology across Australia, New Zealand, Indonesia and a number of Pacific Island nations.

Managing Director of Greenearth Energy Mark Miller said, “We are delighted to have received this approval and we look forward to successfully commissioning our Port Melbourne demonstration site later this year, the first Z20 demonstration site outside Israel.

“We believe the ZenithSolar Z20 has the potential to efficiently deliver the dual benefits of emissions free power and hot water to a wide range of customers. We look forward to successfully delivering our Victorian trial and moving to full distribution within Australia and the wider Pacific region.”

To view the official Press Release, please click here.